40 related articles for article (PubMed ID: 37463687)
1. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.
Marzo B; Vidal-Jordana A; Castilló J; Robles-Sanchez MA; Otero-Romero S; Tintore M; Montalban X; Buti M; Riveiro-Barciela M
J Neurol; 2024 Jan; 271(1):134-140. PubMed ID: 37695530
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ko PH; Kuo MH; Kao IT; Wu CY; Tseng CW; Shao SC
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257778
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
6. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab.
Haider M; Flocco G; Lopez R; Carey W
BMJ Open; 2020 Dec; 10(12):e043672. PubMed ID: 33323450
[TBL] [Abstract][Full Text] [Related]
7. Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma.
Torres HA; Mustafayev K; Nastoupil LJ; Shelburne SA
Lancet; 2024 Apr; 403(10434):1372-1373. PubMed ID: 38582568
[No Abstract] [Full Text] [Related]
8. Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy - A systematic review and meta-analysis.
Maung ST; Deepan N; Decharatanachart P; Chaiteerakij R
Asia Pac J Clin Oncol; 2024 Mar; ():. PubMed ID: 38512893
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.
Jang H; Yu SJ; Lee HG; Kim TM; Lee YB; Cho EJ; Lee JH; Yoon JH; Kim YJ
J Korean Med Sci; 2023 Jul; 38(28):e216. PubMed ID: 37463687
[TBL] [Abstract][Full Text] [Related]
12. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M; Manzano ML; Morillas RM; García-Retortillo M; Martín L; Prieto M; Gutiérrez ML; Suárez E; Gómez Rubio M; López J; Castillo P; Rodríguez M; Zozaya JM; Simón MA; Morano LE; Calleja JL; Yébenes M; Esteban R
PLoS One; 2017; 12(9):e0184550. PubMed ID: 28898281
[TBL] [Abstract][Full Text] [Related]
13. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Kim DY; Kim YR; Suh C; Yoon DH; Yang DH; Park Y; Eom HS; Lee JO; Kwak JY; Kang HJ; Hyun SY; Jo JC; Chang MH; Yoo KH; Lim SN; Shin HJ; Kim WS; Kim IH; Kim MK; Kim HJ; Lee WS; Mun YC; Kim JS
Am J Gastroenterol; 2023 Aug; 118(8):1373-1380. PubMed ID: 36728217
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
